
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4764543/publications.pdf Version: 2024-02-01



DED RECH

#	Article	IF	CITATIONS
1	The WHO-5 Well-Being Index: A Systematic Review of the Literature. Psychotherapy and Psychosomatics, 2015, 84, 167-176.	8.8	2,459
2	Measuring wellâ€being rather than the absence of distress symptoms: a comparison of the SFâ€36 Mental Health subscale and the WHOâ€Five wellâ€being scale. International Journal of Methods in Psychiatric Research, 2003, 12, 85-91.	2.1	751
3	Reliability and validity of the Japanese version of the World Health Organizationâ€Five Wellâ€Being Index in the context of detecting depression in diabetic patients. Psychiatry and Clinical Neurosciences, 2007, 61, 112-119.	1.8	197
4	A Double-Blind, Placebo-Controlled Study of Sertraline in the Prevention of Depression in Stroke Patients. Psychosomatics, 2003, 44, 216-221.	2.5	189
5	Rating Scales for Psychopathology, Health Status and Quality of Life. , 1993, , .		170
6	Mental Pain and Suicide: A Systematic Review of the Literature. Frontiers in Psychiatry, 2016, 7, 108.	2.6	169
7	The Concept of Euthymia. Psychotherapy and Psychosomatics, 2016, 85, 1-5.	8.8	158
8	Psychometric evaluation of the Major Depression Inventory (MDI) as depression severity scale using the LEAD (Longitudinal Expert Assessment of All Data) as index of validity. BMC Psychiatry, 2015, 15, 190.	2.6	126
9	The construct validity of the Perceived Stress Scale. Journal of Psychosomatic Research, 2016, 84, 22-30.	2.6	114
10	Clinimetrics and Clinical Psychometrics: Macro- and Micro-Analysis. Psychotherapy and Psychosomatics, 2012, 81, 333-343.	8.8	100
11	Rating scales in depression: limitations and pitfalls. Dialogues in Clinical Neuroscience, 2006, 8, 207-215.	3.7	94
12	A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D ₆). Psychotherapy and Psychosomatics, 2017, 86, 141-149.	8.8	85
13	The Bech-Rafaelsen Mania Scale in Clinical Trials of Therapies for Bipolar Disorder. CNS Drugs, 2002, 16, 47-63.	5.9	82
14	The Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties. Psychotherapy and Psychosomatics, 2011, 80, 10-27.	8.8	75
15	Social Functioning. CNS Drugs, 2005, 19, 313-324.	5.9	72
16	Escitalopram dose–response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. International Journal of Neuropsychopharmacology, 2004, 7, 283-290.	2.1	68
17	Prevalence of depression, quality of life and antidepressant treatment in the Danish General Suburban Population Study. Nordic Journal of Psychiatry, 2014, 68, 507-512.	1.3	60
18	A clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R) in general population studies (Denmark, Norway, and Italy). Nordic Journal of Psychiatry, 2016, 70, 374-379.	1.3	59

#	Article	IF	CITATIONS
19	Preferred Place of Care and Death in Terminally Ill Patients with Lung and Heart Disease Compared to Cancer Patients. Journal of Palliative Medicine, 2017, 20, 1217-1224.	1.1	54
20	Psychosocial predictors of treatment outcome for trauma-affected refugees. Högre Utbildning, 2016, 7, 30907.	3.0	51
21	Dose–response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology, 2006, 188, 273-280.	3.1	50
22	Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks. Psychotherapy and Psychosomatics, 2017, 86, 134-140.	8.8	42
23	Rating scales for mood disorders: Applicability, Consistency and construct validity. Acta Psychiatrica Scandinavica, 1988, 78, 45-55.	4.5	40
24	The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naA¯ve Type 2 diabetes: a placebo-controlled, multicentre study. Quality of Life Research, 2003, 12, 413-425.	3.1	39
25	The Validity of the Different Versions of the Hamilton Depression Scale in Separating Remission Rates of Placebo and Antidepressants in Clinical Trials of Major Depression. Journal of Clinical Psychopharmacology, 2016, 36, 453-456.	1.4	39
26	Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study. BMC Psychiatry, 2016, 16, 383.	2.6	39
27	Modafinil augmentation in depressed patients with partial response to antidepressants: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). Nordic Journal of Psychiatry, 2005, 59, 173-178.	1.3	38
28	Clinimetric Dilemmas in Outcome Scales for Mental Disorders. Psychotherapy and Psychosomatics, 2016, 85, 323-326.	8.8	37
29	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC). Journal of Affective Disorders, 2014, 163, 18-24.	4.1	36
30	MYPLAN –mobile phone application to manage crisis of persons at risk of suicide: study protocol for a randomized controlled trial. Trials, 2017, 18, 171.	1.6	36
31	The Day-to-Day Acute Effect of Wake Therapy in Patients with Major Depression Using the HAM-D6 as Primary Outcome Measure: Results from a Randomised Controlled Trial. PLoS ONE, 2013, 8, e67264.	2.5	33
32	Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D 6) as outcome measure. Journal of Affective Disorders, 2016, 190, 842-845.	4.1	31
33	Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. Journal of Affective Disorders, 2014, 160, 68-73.	4.1	29
34	Health of the Nation Outcome Scales (HoNOS): Implementability, subscale structure and responsiveness in the daily psychiatric hospital routine over the first 18 months. Nordic Journal of Psychiatry, 2003, 57, 285-290.	1.3	27
35	The Hamilton Depression Scale (HAM-D) and the Montgomery–Ãsberg Depression Scale (MADRS). A psychometric re-analysis of the European Genome-Based Therapeutic Drugs for Depression Study using Rasch analysis. Psychiatry Research, 2014, 217, 226-232.	3.3	27
36	Test-retest reliability and measurement error of the Danish WHO-5 Well-being Index in outpatients with epilepsy. Health and Quality of Life Outcomes, 2018, 16, 175.	2.4	27

#	Article	IF	CITATIONS
37	The responsiveness of the different versions of the <scp>H</scp> amilton Depression Scale. World Psychiatry, 2015, 14, 309-310.	10.4	25
38	The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. Schizophrenia Bulletin, 2018, 44, 453-462.	4.3	25
39	Clinical and psychometric validation of the psychotic depression assessment scale. Journal of Affective Disorders, 2015, 173, 261-268.	4.1	24
40	Evaluating psychiatric symptoms in Parkinson's Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 131-137.	4.8	24
41	Somatization in Parkinson's Disease: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 78, 18-26.	4.8	23
42	Rating scales in general practice depression: Psychometric analyses of the Clinical Interview for Depression and the Hamilton Rating Scale. Journal of Affective Disorders, 2015, 171, 68-73.	4.1	22
43	Patient reported outcome measures (PROMs): examination of the psychometric properties of two measures for burden of symptoms and quality of life in patients with depression or anxiety. Nordic Journal of Psychiatry, 2018, 72, 251-258.	1.3	22
44	The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study. Nordic Journal of Psychiatry, 2018, 72, 442-446.	1.3	22
45	Pressure pain sensitivity: A new method of stress measurement in patients with ischemic heart disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 373-379.	1.2	20
46	Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: a randomized, double-blind controlled study. Acta Neuropsychiatrica, 2014, 26, 272-279.	2.1	20
47	The clinical effect of clomipramine in chronic idiopathic pain disorder revisited using the Spielberger State Anxiety Symptom Scale (SSASS) as outcome scale. Journal of Affective Disorders, 2009, 119, 43-51.	4.1	18
48	Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI). Nordic Journal of Psychiatry, 2018, 72, 431-436.	1.3	17
49	Neuroticism, depression and anxiety in takotsubo cardiomyopathy. BMC Cardiovascular Disorders, 2016, 16, 118.	1.7	16
50	Anxiety in adolescent epilepsy. A clinimetric analysis. Nordic Journal of Psychiatry, 2016, 70, 424-429.	1.3	16
51	SCL-90-R emotional distress ratings in substance use and impulse control disorders: One-factor, oblique first-order, higher-order, and bi-factor models compared. Psychiatry Research, 2017, 255, 173-185.	3.3	16
52	Relapse Prevention and Residual Symptoms. Journal of Clinical Psychiatry, 2010, 71, 121-129.	2.2	16
53	Measurement by observations of aggressive behaviour and activities in clinical situations. Criminal Behaviour and Mental Health, 1994, 4, 290-302.	0.8	15
54	Quality-of-Life Measurements for Patients Taking Which Drugs?. Pharmacoeconomics, 1995, 7, 141-151.	3.3	15

#	Article	IF	CITATIONS
55	The prevalence of psychological distress in Parkinson's disease patients: The brief symptom inventory (BSI-18) versus the Hopkins symptom checklist (SCL-90-R). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 96-101.	4.8	15
56	Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). Journal of Affective Disorders, 2016, 190, 111-114.	4.1	14
57	Measuring quality of life: The medical perspective. Nordic Journal of Psychiatry, 1992, 46, 85-89.	1.3	13
58	Eysenck's Two Big Personality Factors and Their Relationship to Depression in Patients with Chronic Idiopathic Pain Disorder: A Clinimetric Validation Analysis. , 2012, 2012, 1-9.		13
59	The construct validity of the Major Depression Inventory: A Rasch analysis of a self-rating scale in primary care. Journal of Psychosomatic Research, 2017, 97, 70-81.	2.6	13
60	Effect of supervised exercise in groups on psychological well-being among pregnant women at risk of depression (the EWE Study): study protocol for a randomized controlled trial. Trials, 2017, 18, 210.	1.6	12
61	The Family Assessment Device: A Clinimetric Analysis. Psychotherapy and Psychosomatics, 2016, 85, 241-243.	8.8	11
62	An overview of which health domains to consider and when to apply them in measurement-based care for depression and anxiety disorders. Nordic Journal of Psychiatry, 2018, 72, 367-373.	1.3	11
63	Pharmacological Treatment of Depressive Disorders: A Review. , 2003, , 89-160.		9
64	The Diagnostic Apathia Scale predicts a dose–remission relationship of T-PEMF in treatment-resistant depression. Acta Neuropsychiatrica, 2015, 27, 1-7.	2.1	9
65	The validity of dysthymia to predict clinical depressive symptoms as measured by the Hamilton Depression Scale at the 5-year follow-up of patients with first episode depression. Nordic Journal of Psychiatry, 2016, 70, 563-566.	1.3	9
66	The Items Predicting Non-Remission after 6 Months of Treatment of Patients with Generalized Anxiety Disorder Covered the Eysenck Neuroticism Components of Anxiety, Interpersonal Sensitivity and Depression. Psychotherapy and Psychosomatics, 2016, 85, 229-230.	8.8	9
67	Transcranial pulsed electromagnetic fields for treatment-resistant depression: A multicenter 8-week single-arm cohort study. European Psychiatry, 2020, 63, e18.	0.2	9
68	Psychometric analysis of the Melancholia Scale in trials with non-pharmacological augmentation of patients with therapy-resistant depression. Acta Neuropsychiatrica, 2014, 26, 155-160.	2.1	8
69	Pharmacological Treatment of Depressive Disorders: A Review. , 2001, , 89-159.		7
70	Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: Evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss. Nordic Journal of Psychiatry, 2005, 59, 205-208.	1.3	7
71	Family psychoeducation for major depressive disorder – study protocol for a randomized controlled trial. Trials, 2016, 17, 427.	1.6	7
72	The Relationship between Sleep Length and Restorative Sleep in Major Depression: Results from the Danish General Suburban Population Study. Psychotherapy and Psychosomatics, 2016, 85, 45-46.	8.8	7

#	Article	IF	CITATIONS
73	The Reliable Change Index (RCI) of the WHO-5 in primary prevention of mental disorders. A measurement-based pilot study in positive psychiatry. Nordic Journal of Psychiatry, 2018, 72, 404-408.	1.3	7
74	Neuroticism (Eysenck's Theory). , 2016, , 1-4.		7
75	A 2-year follow-up study of patients participating in our transcranial pulsating electromagnetic fields augmentation in treatment-resistant depression. Acta Neuropsychiatrica, 2015, 27, 119-125.	2.1	6
76	A clinimetric analysis of a BPRS-6 scale for schizophrenia severity. Acta Neuropsychiatrica, 2018, 30, 187-191.	2.1	6
77	Problems in measuring quality of life in schizophrenia. Nordic Journal of Psychiatry, 1990, 44, 77-79.	0.1	5
78	Hemodynamic responses to mental stress during salt loading. Clinical Physiology and Functional Imaging, 2017, 37, 688-694.	1.2	5
79	A confirmative clinimetric analysis of the 36-item Family Assessment Device. Nordic Journal of Psychiatry, 2018, 72, 268-272.	1.3	5
80	Multiâ€Axial Classification of Depression: MULTI LADâ€2 Case Record System. Acta Psychiatrica Scandinavica, 1983, 68, 85-102.	4.5	4
81	The time has come to stop rotations for the identification of structures in the Hamilton Depression Scale (HAM-D17). Revista Brasileira De Psiquiatria, 2013, 35, 360-363.	1.7	4
82	Extraversion-Introversion (Eysenck's Theory). , 2016, , 1-3.		4
83	Concept of Mild Endogenous Depression. British Journal of Psychiatry, 1987, 151, 271-271.	2.8	3
84	A short historical review of SCNP with special reference to the UKU. Acta Neuropsychiatrica, 2014, 26, 4-7.	2.1	3
85	A Major Clinimetric Dilemma in Self-Reported Outcome Scales: Mixing Positively and Negatively Worded Items. Psychotherapy and Psychosomatics, 2017, 86, 124-125.	8.8	3
86	Individual quality of life in schizophrenic patients – description and applicability of GRIDQoL in a computer-based version. International Journal of Methods in Psychiatric Research, 2001, 10, 134-139.	2.1	2
87	Modern Psychometric Approaches to Analysis of Scales for Health-Related Quality of Life. , 2016, , 103-120.		2
88	Effects of Long-Term Treatment with T-PEMF on Forearm Muscle Activation and Motor Function in Parkinson's Disease. Case Reports in Neurology, 2018, 10, 242-251.	0.7	2
89	Health-Related Quality of Life. Annals of Medicine, 1993, 25, 103-104.	3.8	1
90	Karl Rickels: A Tribute on His 90th Birthday. Psychotherapy and Psychosomatics, 2014, 83, 131-135.	8.8	1

0

#	Article	IF	CITATIONS
91	Negative Mental Health: The Ordinary Mental Disorders. Categories Versus Dimensions. SpringerBriefs in Psychology, 2016, , 1-7.	0.2	1
92	Measuring chronic pain. Pain, 2016, 157, 1574-1574.	4.2	1
93	Prospective psychometric characterization of hip and knee arthroplasty patients. Nordic Journal of Psychiatry, 2018, 72, 39-44.	1.3	1
94	How to Measure the Personality. , 2018, , 17-32.		1
95	The relationship between self-reported general health and observed depression and anxiety in cancer patients during chemotherapy. Nordic Journal of Psychiatry, 1995, 49, 25-31.	1.3	0
96	18-month maintenance treatment with sertraline may have sustained psychosocial benefits in chronic depression. Evidence-Based Mental Health, 2003, 6, 49-49.	4.5	0
97	Measuring the mind. Conceptual issues in contemporary psychometrics. Acta Psychiatrica Scandinavica, 2006, 114, 70-70.	4.5	0
98	Clinician-Administered Symptom Scales Within the Basic Diagram. SpringerBriefs in Psychology, 2016, , 31-42.	0.2	0
99	Positive Mental Health. SpringerBriefs in Psychology, 2016, , 43-47.	0.2	0
100	Response to "An Evolutionary Approach to Clinical Pharmacopsychology― Psychotherapy and Psychosomatics, 2017, 86, 372-372.	8.8	0
101	S46. THE VALIDITY AND SENSITIVITY OF PANSS-6 IN TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S341-S342.	4.3	0
102	The Basic Diagram of Personality Dimensions. SpringerBriefs in Psychology, 2016, , 9-13.	0.2	0
103	Extraversion-Introversion (Eysenck's Theory). , 2020, , 1520-1522.		0

104 Neuroticism (Eysenck's Theory). , 2020, , 3227-3230.